Market Overview

Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial with PCSK9 Antibody for Hypercholesterolemia

Share:
Related SNY
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
CVS Says New Cholesterol Drug Types Could Be Costly
VIVUS Q1 Loss Narrower-than-Expected, Revenues Beat - Analyst Blog (Zacks)
Related REGN
Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks
Regeneron Earnings: Small Growth Expected, Driven By Eylea
Stocks End Lower On Yellen Comment; Biotechs Bounce Back (Investor's Business Daily)

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients. SAR236553/REGN727 is an investigational subcutaneously administered, fully-human antibody that is being evaluated for its impact on lowering low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The ODYSSEY OUTCOMES trial will enroll approximately 18,000 patients, who recently suffered an acute coronary syndrome (ACS), from 49 countries across six continents. With the start of this study, eleven trials are now recruiting in the global SAR236553/REGN727 Phase 3 program.

Posted-In: News FDA

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters